31 results about "Male contraceptive" patented technology

The invention relates to compositions and methods for effecting male contraception.

This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of acute and / or chronic muscular wasting conditions; e) preventing and / or treating dry eye conditions; f) oral androgen replacement therapy; and / or g) decreasing the incidence of, halting or causing a regression of prostate cancer.

The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.

Methods for treating FSH related conditions, such as prostatic intraepithelial neoplasia, pedophilia, infertility, or vaginal bleeding, with GnRH antagonists are disclosed. The methods of the invention generally feature administering to a subject a GnRH antagonist suitable for in vivo administration and able to reduce both plasma FSH and LH levels in a subject, in an amount or in a formulation effective to reduce plasma FSH levels in the subject to a symptom alleviating level. In vitro fertilization and male contraceptive methods are also provided.

The invention relates to beta-defensin 15 of specific antibacterial peptides of rat epididymis and application thereof, in particular to Defb15 genes of rats or orthologous genes thereof or application of amino acid sequences of the Defb15 genes or the orthologous genes thereof in the preparation of medicines for regulating and controlling male fertility, the development of male contraceptive medicines and the preparation of medicines for diagnosing and treating male infertility and resisting genital tract infection. The invention also relates to a medicinal composition containing the genes or the amino acid sequences.

The invention discloses a seminiferous duct contraceptive suppository conveyor which comprises a sleeve pipe, wherein the front end of the sleeve pipe is provided with a positioning cavity; a cavity is arranged in the sleeve pipe; the front end of the sleeve pipe is provided with a suppository seat; the rear end of the suppository seat is provided with a positioning column; the positioning columnis inserted in and matched with the positioning cavity; suppository seat cavities are arranged from the positioning column to the front end of the suppository seat in the suppository seat; the front end of the suppository seat is bent to one side; the front end of the suppository seat is provided with a needle seat; a needle head is installed on the needle seat, and a guide rod is installed in the cavity; a guide rod inner cavity is arranged in the guide rod, and a guide thread is installed in the guide rod inner cavity. A memory alloy silica gel mesh duct-shaped seminiferous duct contraceptive suppository matched with the seminiferous duct contraceptive suppository conveyor comprises a suppository body, wherein an inner cavity is arranged in the suppository body, and one end of the suppository body is provided with a suppository body opening; two silica gel spacers are installed in the inner cavity in parallel; and the periphery of the suppository body is provided with a silica gel layer. The invention overcomes the defects that male contraceptive methods are few at present, and only one long-term measure of vasoligature is available, and provides technical support and a contraceptive device for improving males to participate in family planning.